mRNA-based therapeutic cancer vaccine enters Phase II trial
Source: European Pharmaceutical Review, June 2021
BioNTech is evaluating its investigational therapeutic mRNA-based cancer vaccine, BNT111, in combination with Libtayo® (cemiplimab) for the treatment of melanoma. The first patient has been treated with BioNTech’s messenger RNA (mRNA) BNT111 cancer vaccine in a Phase II trial.
